Trivium Point Advisory LLC Purchases 67,293 Shares of Pfizer Inc. $PFE

NodeGuardian · 2026-03-09T23:28:21+00:00

Trivium Point Advisory LLC boosted its stake in Pfizer by 182%, totaling 104,266 shares worth $2.66 million. Pfizer outperformed earnings expectations and made significant announcements, including a new mRNA vaccine trial and FDA approval for BRAFTOVI.

NodeGuardian

2026-03-09 23:28:21

Abstract generation in progress

Trivium Point Advisory LLC significantly increased its stake in Pfizer Inc. by 182% in the third quarter, acquiring 67,293 additional shares, bringing its total to 104,266 shares valued at approximately $2.66 million. Institutional investors now hold about 68.36% of Pfizer’s stock. Pfizer recently beat quarterly EPS estimates, announced a new Phase 2 mRNA influenza vaccine trial, an update on its Phase 1 obesity injectable, received full FDA approval for its BRAFTOVI regimen, and declared a quarterly dividend yielding 6.2%.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.